Clinical study data of DCP-001 in AML published in leading journal for new concepts and advances in cancer immunology and immunotherapy

Clinical study data of DCP-001 in AML published in leading journal for new concepts and advances in cancer immunology and immunotherapy.

Leiden, The Netherlands, 26 July 2018 – DCprime announces that the results of the phase I study with its lead product DCP-001 in AML have been published in Cancer Immunology, Immunotherapy.

The phase I study was conducted with DCP-001 in 12 advanced-stage elderly AML patients. Primary objectives of the study (feasibility and safety) were achieved with 10 out of the 12 patients completing the vaccination program. Treatment was well tolerated and it is concluded that DCP-001 in elderly AML patients is safe, feasible and generates both cellular and humoral immune responses.

Prof Dr Arjan van de Loosdrecht, Amsterdam UMC, VU University Medical Center, The Netherlands commented: “We are very glad that the phase-I study with the DCP-001 vaccine in AML is published, showing that it is safe, feasible and well tolerated. In addition, the vaccine generates both cellular and humoral immune responses and maintenance of these responses are observed in patients with a relatively long survival, suggesting a possible correlation. We are looking forward to the data of the phase-2 study, ADVANCE-II for patients with AML in complete remission after induction therapy with persistence of minimal residual disease, which is currently open for inclusion.”

Dr Erik Manting, CEO of DCprime added: “Compliments to Prof Dr Arjan van de Loosdrecht and Prof Dr Tanja de Gruijl at VU University Medical Center and all others including our DCprime colleagues who contributed to this publication on the clinical study data with DCP-001 in AML. It underlines the promise and potency of the DCOne® platform, which we continue to explore in AML and other cancer types.”

About DCprime bv

DCprime is a privately owned, clinical stage biotechnology company focused on cancer immunotherapies. Founded in 2005, DCprime currently develops cell based cancer vaccines based on its proprietary technology platform DCOne®, with lead DCOne® asset DCP-001 being studied in patients with acute myeloid leukemia (AML). A completed Phase I study has demonstrated that DCP-001 is generally safe and capable of inducing a broad immune response. DCprime has received orphan drug designation from the European Medicines Agency for DCP-001 in AML and has commenced a multi-centre Phase II trial. DCprime intends to develop DCOne®-based vaccines in other cancer indications, including multiple myeloma and solid tumours. For more information, visit


Dr Erik Manting
CEO DCprime bv

Posted in PR